ACOG — Alpha Cognition Inc. Common Stock

Summary of ACOG Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Product Revenues: $3.5 million, a 40% increase from Q4 2025 ($2.5 million).
• Year-over-Year Comparison: Q1 2025 revenues were $347,000, reflecting significant growth since the commercial launch.
• Operating Expenses: Approximately $11.6 million, up from $10.7 million in Q4 2025 and $6.3 million in Q1 2025, driven by investments in commercial infrastructure and clinical studies.
• Net Loss: $6.5 million or $0.30 per share, compared to a loss of $1.7 million or $0.11 per share in Q1 2025.
• Cash Position: $54.2 million as of March 31, 2026, down from $66 million at the end of 2025, with a debt-free balance sheet.

2. Strategic Updates and Business Highlights

• ZUNVEYL Commercialization: The company is in its fourth quarter of ZUNVEYL commercialization, showing strong prescriber adoption and demand, particularly in long-term care.
• Prescription Metrics:
  • Bottles dispensed grew 23% quarter-over-quarter.
  • 1,060 active prescribers, a 23% increase from Q4 2025, with a 75% repeat prescription rate.
  • Nursing homes with ZUNVEYL prescriptions increased by 25%.
• Clinical Programs: Three active real-world studies (Beacon, CONVERGE, RESOLVE) are underway, with Beacon expected to report top-line data by early Q3 2026.
• Intellectual Property: Two new patents issued extending protection for ZUNVEYL through 2045, including a new indication for treating traumatic brain injury (TBI), representing a $14 billion market opportunity.
• Sales Team Expansion: A 60-person customer-facing team was established to enhance market reach and engagement.

3. Forward Guidance and Outlook

• Operating Profitability: The company aims to achieve operating profitability by 2027.
• 2026 Operating Expense Guidance: Reiterated at $54 million to $58 million, with expected modest increases in Q2 due to ramping clinical studies.
• Revenue Guidance: No specific revenue guidance provided for Q2, but strong growth momentum is anticipated to continue.

4. Bad News, Challenges, or Points of Concern

• Payer Access: Payer access remains a significant challenge, with only 16% of contracted plans fully implemented. The company is actively working to improve this situation.
• Net Loss: The increase in net loss year-over-year raises concerns about the sustainability of current spending levels.
• Market Dynamics: The company acknowledges that payer access is a timing issue rather than a demand problem, indicating potential delays in broader market adoption.

5. Notable Q&A Insights

• Prior Authorization: No significant changes in prior authorization requirements noted, with an approval rate of approximately 89% when support is provided.
• Sublingual Formulation: A pharmacokinetic study for the sublingual formulation is set to begin, with potential IND submission anticipated later in 2026.
• Clinical Study Data: Beacon study completion is ahead of schedule, with significant data expected to support ZUNVEYL's efficacy and tolerability in long-term care settings.
• Sales Force Productivity: Continued improvement in sales force productivity is expected as the team becomes more established, with AI tools being leveraged for better targeting and efficiency.

Overall, Alpha Cognition demonstrated strong commercial growth in Q1 2026, with a focus on expanding prescriber adoption and enhancing payer access, while navigating challenges related to operating losses and market dynamics.